Ordering Recommendation

Use to detect drug exposure from among a targeted list of prescriptions, over-the-counter medications, and illicit drugs; for a complete list of drugs and drug metabolites detected, refer to Additional Technical Information. Not recommended to determine medication compliance or to assess for undisclosed drug/substance use in the context of pain management, substance use disorder treatment, or any other pharmacotherapies involving controlled substances.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Plain red (no additives, serum gel or SST tubes are not acceptable), grey-top (NaF/oxalate), lavender (K2 or K3EDTA) or pink (K2EDTA).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 4 mL of serum or plasma into an ARUP Standard Transport Tube. (Min: 2 mL)

Storage/Transport Temperature


Unacceptable Conditions

Gel Separator tubes or light blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Postmortem specimens.


After separation from cells: Ambient: 24 hours; Refrigerated: 2 weeks; Frozen: 2 months.


Qualitative Liquid Chromatography-Tandem Mass Spectrometry


Mon, Fri


1-8 days

Reference Interval

By report

Interpretive Data

The drug screen panel can detect 127 drugs and drug metabolites by LC-MS/MS.  The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

This assay is for medical purposes only; not valid for forensic use

For a complete list of drugs and drug metabolites detected, refer to the Additional Technical Information.

This test was developed, and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)


If a specimen drug class is reported as positive, the test will report the confirmed component from the comprehensive drug class at no additional charge. (Classes include ARUP test codes 3005045, 3005046, 3005047, 3005048, 3005049, 3005050, 3005051, 3005052, 3005053, 3005054, 3005055, 3005056, 3005057, 3005058, or 3005059.)

Hotline History


CPT Codes

80323; 80326; 80329; 80334; 80337; 80338; 80341; 80344; 80346; 80348; 80353; 80354; 80356; 80357; 80358; 80359; 80360; 80361; 80363; 80365; 80366; 80368; 80370; 80371; 80372; 80373; 80377; 83992 (Alt code: G0482)


Component Test Code* Component Chart Name LOINC
3004834 Anticoagulants, Serum/Plasma
3004835 Antihistamines, Serum/Plasma
3004836 Cardiac, Serum/Plasma
3004837 Anticonvulsants, Serum/Plasma
3004838 Antidepressants, Serum/Plasma
3004839 Antipsychotics, Serum/Plasma
3004840 Nicotine, Serum/Plasma 61128-5
3004841 Opioids, Serum/Plasma
3004842 Cough Suppressants, Serum/Plasma 3538-6
3004843 NSAIDs, Serum/Plasma 3297-9
3004844 Benzodiazepines, Serum/Plasma
3004845 Muscle Relaxants, Serum/Plasma
3004846 Sedative-Hypnotics, Serum/Plasma
3004847 Stimulants, Serum/Plasma
3004848 Antidiabetics, Serum/Plasma
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • Blood Screen
  • Comprehensive drug screen
  • Drug Analysis
  • general toxicology
  • Multiple Drug Analysis
  • Tox Screen
Drug Profile, Expanded Targeted Panel by LC-MS/MS, Serum/Plasma